The Future of the Delivery of Modern Medicine
The Future of the Delivery of Modern Medicine in St. James’s Hospital and the Trinity College Dublin Clinical Research Facility in Dublin 7-8th July. Thanks
Menu
AN INTERNATIONAL NETWORK OF HOSPITAL CENTRE OF CELL THERAPY EXCELLENCE BASED GMP MANUFACTURING ATMP PODs
aCGT Vector’s focus is Cellular Therapy, rapidly evolving as a therapeutic approach that brings tremendous hope to patients, their families and clinicians; for the treatment of rare diseases, most critically cancer. Less than 5% of patients suffering from rare diseases today have any therapeutic option available to them.
Cell Therapy
aCGT Vector’s Cellular Therapy procedures will involve collecting patients‘ own immune cells and bringing them safely to its GMP facility inside the hospital for process engineering and potential exponential expansion in volume, to make these immune cells more strategically effective, before being administered back into the same patient.
AUTOLOGOUS CELLULAR THERAPY
The safest and most certain approach being taken today, where the patients’ own immune cells are removed, transformed and potentially expanded in volume using aCGT Vector’s modern closed-ex-vivo-system technology and state of the art GMP facility.
The modified immune cells are then re-infused back into the same patient to target and treat their own rate disease. This entirely avoids any and all risks of their own immune system identifying these incoming cells as foreign and rejecting them which could prove fatal to often immune system compromised patients.
Small text
EU-BASED CELL THERAPY BUSINESS
ATMP GMP-in-a-BOX in Cellular Therapy hospital centres of excellence.
GMP-in-a-POD
The Future of Cell Therapy is Modular Agile Digitised Interconnected GMP-in-a-POD
stay up to date
Read all about out current treatments, processes and upcoming events
Mayo man first in Ireland to receive groundbreaking cell therapy for cancer
Patients requiring CAR-T immunotherapy previously had to travel to UK for treatment A Co Mayo man has become the first patient in Ireland to receive groundbreaking cell therapy treatment
Room for allogeneic and autologous product in the cell therapy space says panel
Allogeneic products may dominate the cell therapy sector thanks to tech and cost advantages but there will always be room for autologous treatments, say experts.
We are pleased to be joining the Nigel and the Team in the campaign, and to support That’s NIce in their journey across the US, 50 states in 50 days!
The Road To 50 States! Discovering the Future of Healthcare After achieving what was previously thought impossible – 25 European countries in 25 days –
HEALED CONSORTIUM SUCCESSFUL IN A €10.5M DTIF-SUPPORTED PROGRAMME
Healed Consortium succesful in a €10.5M DTIF-Supported programme to develop groundbreaking new therapies for currently incurable cancers. We are delighted to announce the success of
ADDRESSING THE RISKS IN THE VEIN TO VEIN CELL THERAPY SUPPLY CHAIN
Lonza, Vineti team up to address risks in the ‘vein-to-vein’ supply chain Lonza enters a partnership with Vineti to advance its ‘vein-to-vein’ delivery network, creating
CONTACT US
© aCGT Vector – All Rights Reserved
Adress
aCGT Vector DAC,
The Mill Enterprise Hub,
Newtown Link Road,
Greenhills, Drogheda,
Co. Louth, A92 CD3D,
Republic of Ireland,
Europe
Contact
+353 864667889